About Bolder Science

Our mission is to provide healthcare professionals with unbiased clinical research information, easily.

Currently, you can access the following clinical trials being conducted worldwide:

359,057 studies
in
219 countries
Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 01/22/2021.
This website is for US healthcare professionals

Log In to Bolder Science

or

Don't have an account? Sign Up

Please enter your email address.

You will receive a link to create a new password via email.

Log In

Create an Account

or
(optional) ?

Welcome, !

Please complete the following 4 questions to ensure you receive the information that best suits your needs.

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

finding clinical trials in which to enroll my patients

Rarely Often

finding newly launched clinical trials (for all phases)

Rarely Often

updates on status changes for clinical trials

Rarely Often

pipeline molecules

Rarely Often

Drug Interventions

Enter up to 3 drug interventions you are currently interested in:

Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 01/22/2021.

Using Virtual Reality (VR) Models for Robotic Prostatectomy

Clinicaltrials.gov identifier NCT03943368

Recruitment Status Enrolling by invitation

First Posted May 9, 2019

Last update posted July 17, 2020

Study Description

Brief summary:

A prospective, randomized, controlled study designed to assess whether digital virtual reality (VR) models, created from existing CT scans and MRIs, provide surgeons with an improved understanding of their patients' anatomy, resulting in more efficient operations (robotic prostatectomy) and improved patient care.

  • Condition or Disease:Prostate Cancer
  • Intervention/Treatment: Device: Ceevra Reveal
  • Phase: N/A
Detailed Description

N/A

Study Design
  • Study Type: Interventional
  • Estimated Enrollment: 20 participants
  • Allocation: Randomized
  • Intervention Model: Parallel Assignment
  • Masking: Single (Participant)
  • Primary Purpose: Treatment
  • Official Title: Using Virtual Reality (VR) Models for Robotic Prostatectomy
  • Actual Study Start Date: April 2019
  • Estimated Primary Completion Date: September 2020
  • Estimated Study Completion Date: June 2021
Arms and interventions
Arm Intervention/treatment
Experimental: Experimental: Intervention Arm
Subjects whose surgeon will be viewing VR models in addition to the source CT/MR image in connection with the case.
Device: Ceevra Reveal
VR models generated using Ceevra Reveal are viewed by surgeons in connection with the case in addition to source CT/MR image.
Outcome Measures
  • Primary Outcome Measures: 1. Total operative time [ Time Frame: During procedure, not to exceed 12 hours ]
  • Secondary Outcome Measures: 1. Postoperative oncologic stage (T stage) [ Time Frame: Measured up to 3 months after discharge ]
  • 2. Readmission [ Time Frame: Measured up to 6 months after discharge ]
  • 3. Postoperative prostate-specific antigen (PSA) [ Time Frame: Measured up to 12 months after discharge ]
  • 4. Patient hospital stay [ Time Frame: Measured at time of patient discharge, up to 10 days ]
  • 5. Positive tumor margin (assessed via standard post-operative biopsy) [ Time Frame: Measured 1-2 weeks after discharge ]
  • 6. Postoperative Gleason Score [ Time Frame: Measured up to 3 months after discharge ]
  • 7. Blood loss (measured in cubic centimeters) [ Time Frame: Measured at end of procedure, not to exceed 12 hours ]
  • 8. Intraoperative conversion from robotic assisted laparoscopic procedure to open procedure [ Time Frame: During procedure, not to exceed 12 hours ]
  • 9. Intraoperative complication [ Time Frame: During procedure, not to exceed 12 hours ]
  • 10. Postoperative erectile function [ Time Frame: Measured via survey up to 18 months after discharge ]
  • 11. Postoperative continence [ Time Frame: Measured via survey up to 18 months after discharge ]
Eligibility Criteria
  • Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
  • Sexes Eligible for Study: Male
  • Accepts Healthy Volunteers: No
Criteria

Inclusion Criteria:

- Patient is undergoing robotic prostatectomy being performed by participating surgeon

- Patient is willing to be randomized between intervention and control arms

Exclusion Criteria:

- Patients with prior pelvic radiation

- Patients with prior androgen deprivation therapy

- Patients with prior localized ablative therapy

- Patients with prior TURP or other surgical BPH treatment

Contacts and Locations
Contacts
Locations

United States, California
UCLA Urology
Los Angeles

United States, California
UC Irvine
Orange

United States, Florida
Mayo Clinic Florida
Jacksonville

United States, New York
Mount Sinai Health System
New York

United States, Washington
Swedish Urology Group
Seattle

United States, Washington
Swedish Medical Center
Seattle

Sponsors and Collaborators

Ceevra, Inc.

Investigators

Principal Investigator: James Porter, MD Swedish Medical Center

Principal Investigator: Raymond Pak, MD Mayo Clinic

Principal Investigator: Thomas Ahlering, MD UC Irvine

Principal Investigator: Robert Reiter, MD UCLA Urology

Principal Investigator: Ketan Badani, MD Mount Sinai Health System

More Information
  • Responsible Party: Ceevra, Inc.
  • ClinicalTrials.gov Identifier: NCT03943368 History of Changes
  • Other Study ID Numbers: 20171006RP
  • First Posted: May 9, 2019 Key Record Dates
  • Last Update Posted: July 17, 2020
  • Last Verified: February 2020
  • Individual Participant
    Data (IPD) Sharing
    Statement:
  • Plan to Share IPD: No
  • Studies a U.S. FDA-regulated Drug Product: No
  • Studies a U.S. FDA-regulated Device Product: Yes
  • Additional relevant MeSH terms: Prostatic Neoplasms